Table 1.
Baseline characteristics of 127 patients participating in the study.
| Characteristics | n (%) |
|---|---|
| TB case | |
| Clinically diagnosed | 47 (37.0) |
| Bacteriologically confirmed | 80 (63.0) |
| smear | 39(48.8) |
| MGIT culture (MTB) | 74(92.5) |
| Xpert | 79(99.0) |
| Resistance pattern (n = 76)* | |
| Resistant to rifampicin (Xpert) or MDR* | 4 (5.2) |
| Resistant to isoniazid only | 7 (9.2) |
| Resistant to isoniazid and pyrazinamide | 1 (1.3) |
| Resistant to streptomycin only | 4 (5.2) |
| Resistant to pyrazinamide only | 2 (2.6) |
| Sex | |
| Male | 74 (58.3) |
| Female | 53 (41.7) |
| CD4 counts/ml (n = 102) | |
| <100 | 35 (34.3) |
| 100-299 | 39 (38.2) |
| >300 | 28 (27.5) |
| On Antiretroviral Treatment | |
| Yes | 75(61.5) |
| No | 47(38.5) |
| Age in years; mean (SD) | 37.1 (10.1) |
| Treatment outcomes | |
| Died | 28(23.1) |
| Completed treatment | 23(19.0) |
| Cured | 49(40.5) |
| Failed | 3(2.5) |
| Lost to follow up | 13(10.7) |
| Not evaluated | 5(4.1) |
Acronyms: SD: standard deviation: Rif: rifampicin; MDR: multidrug resistant. *One rifampicin-resistant case (through Xpert) was not confirmed with MGIT based drug susceptibility testing. One other case with rifampicin resistance was contaminated in MGIT-based drug susceptibility testing.